Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

This is the logo of the provider
ESC 2026 28 - 31 August 2026

Breaking boundaries in cardiometabolic care with oral and injectable GLP-1RAs

Meeting description
ESC - Prof Erin Bohula - Agenda (Subtitles) 0:07 Hello, I'm Doctor Aaron Bahula and I'm delighted to invite you to join me at ESC 2026 for an engaging symposium titled Breaking Boundaries in Cardiometabolic Care with Oral and Injectable GLP One Ras. 0:22 On Saturday, August 29th. 0:25 Together with Professor Sabod Verma and Dominica Rubino, we will be discussing the latest evidence shaping the use of the GLP One receptor agonist in cardiometabolic care with a particular focus on cardiovascular outcomes. 0:39 We will also be discussing emerging clinical insights into oral GLP One RA and consider how oral and injectable formulations may fit into individualized treatment strategies for the management of obesity. 0:52 Then finally, through a discussion of a patient profile, we will examine practical clinical considerations that can help inform treatment decisions and optimize patient care. 1:03 I look forward to your attendance either in person or online at ESC 2026 in Munich on Saturday, August 29th from 12:30 to 1:30 local time for what promises to be a highly stimulating and valuable discussion. 1:17 Thank you and we hope to see you there.
Chair teaser video
Add to Calendar
Download agenda
Saturday, 29 August 2026
12:30 - 12:35
(CEST)

Welcome & introduction

Erin Bohula
12:35 - 12:47
(CEST)

CV outcomes with GLP-1RAs: Evidence beyond a class effect

Subodh Verma
12:47 - 12:59
(CEST)

Oral and injectable GLP-1RAs: A new chapter in CV therapies

Domenica Rubino
12:59 - 13:05
(CEST)

GLP-1RAs in clinical CV guidelines: The latest insights

Erin Bohula
13:05 - 13:23
(CEST)

Where evidence meets practice: Clinical considerations with GLP-1RAs

Erin Bohula, Subodh Verma, Domenica Rubino
13:23 - 13:28
(CEST)

Q&A

Erin Bohula, Subodh Verma, Domenica Rubino
13:28 - 13:30
(CEST)

Closing

Erin Bohula
Keywords
Cardiovascular Disease
Congress industry session
GLP-1 RA
Semaglutide